ARCT Q1 2025 Earnings — Arcturus Therapeutics Holdings Inc. Revenue & Financial Results | Market Cap Arena

ARCTArcturus Therapeutics Holdings Inc.

$217M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$29M-9.9% YoY

Gross Profit

$29M100.0% margin

Operating Income

-$17M-57.3% margin

Net Income

-$14M-47.9% margin

EPS (Diluted)

$-0.52

QoQ Revenue Growth

+39.9%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$35M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$332M

Total Liabilities

$98M

Stockholders' Equity

$234M

Cash & Equivalents

$217M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$29M	$33M	-9.9%
Gross Profit	$29M	$33M	-9.9%
Operating Income	-$17M	-$30M	+44.7%
Net Income	-$14M	-$27M	+47.5%

Revenue Segments

Collaboration Revenue

$25M87%

Grant

$4M13%